Improvement in the neutrophil-lymphocyte ratio after combined FOLFOX chemotherapy for stage III colon cancer is associated with improved minimal resdiual disease and outcome
Date
2022-02-19
item.contributor.advisor
item.page.orcidurl
Journal Title
Journal ISSN
Volume Title
Publisher
Asian pacific journal of cancer prevention
item.page.isbn
item.page.issn
1513-7368
item.page.issne
item.page.doiurl
Abstract
Introduction: Minimal residual disease (MRD) is the net result of the biological properties of disseminated tumour
cells and the effect of the immune system and treatment to eliminate them. The aim of this study was to analyse the
effect of combined chemotherapy on the immune function as determined by the neutrophil-lymphocyte ratio (NLR)
and if it was associated with changes in the subtype of minimal residual disease and outcome in stage III colon cancer.
Methods and Patients: A prospective, single centre observational study; the NLR was determined immediately prior
to and one, two and three months after completing chemotherapy. Circulating tumour cells (CTCs) and bone marrow
micro-metastasis (mM) using immunocytochemistry with anti-CEA were determined prior to and one month after
chemotherapy. The association of changes in the NLR with MRD subtypes classified as Group I (negative for CTCs and
mM), Group II (positive for mM) and Group III (positive for CTCs) as a result of chemotherapy and five-year disease
free progression (DFS) analysed. Results: One hundred and eighty eight patients participated of whom 83 (44.9%)
relapsed. In non-relapsing patients the NLR significantly increased and was higher after chemotherapy compared with
relapsing patients. Significant increases in the NLR were associated with changes to a better MRD prognostic subtype
and decreases with a worse MRD subtype. Neither baseline NLR nor MRD subtype predicted response to chemotherapy.
DFS for MRD subgroups were 88%, 56% and 6% for Groups I to III respectively. Conclusions: Immune function as
measured by the NLR is associated with MRD prognostic subtypes, improvements in the NLR are associated with
improvements in MRD post chemotherapy but neither baseline NLR or MRD predicted outcome.
Description
item.page.coverage.spatial
item.page.sponsorship
Funded by the Western Metropolitan Health Authority.
The research grant paid for direct costs of the study, the
funding source did not participate in the design, collection,
analysis or interpretation of the data, in the writing of the
report, its conclusions or decision to submit the paper for
consideration to be published. The corresponding author
participated actively in the study, had full access to all the
study data and had final responsibility for the decision to
submit the article for publication
Ethical Considerations
The study was approved by the health authorites
ethics and science committee and fully complied with
the Declaration of Helsinki and Chilean law on patient’s
rights. All patients provided written informed consent
prior to their participation.
Due to Chilean law on patients rights and confidentiality
the data are not available for general study purposes.
Conflicts of Interest
The authors report no conflicts of interest